Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company is conducting a Phase ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks.

In the world of oncology drug development, the standard playbook is simple: race to earlier lines of treatment, where patient ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Art Hogan, chief market strategist at B. Riley Wealth, joins BNN Bloomberg to discuss the outlook on the markets and provide ...

Oct 14 (Reuters) - Eli Lilly & Co (LLY.N), opens new tab on Wednesday said other trials of its experimental coronavirus antibody therapy remain on track after a government-run study testing the ...